184 related articles for article (PubMed ID: 37350109)
1. Microbiome modulates immunotherapy response in cutaneous squamous cell carcinoma.
Voigt AY; Walter A; Young TH; Graham JP; Batista Bittencourt BM; de Mingo Pulido A; Prieto K; Tsai KY; Sundberg JP; Oh J
Exp Dermatol; 2023 Oct; 32(10):1624-1632. PubMed ID: 37350109
[TBL] [Abstract][Full Text] [Related]
2. Microbiome modulates immunotherapy response in cutaneous squamous cell carcinoma.
Voigt AY; Walter A; Young T; Graham JP; Batista Bittencourt BM; de Mingo Pulido A; Prieto K; Tsai KY; Sundberg JP; Oh J
bioRxiv; 2023 Jan; ():. PubMed ID: 36747869
[TBL] [Abstract][Full Text] [Related]
3. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.
Gopalakrishnan V; Spencer CN; Nezi L; Reuben A; Andrews MC; Karpinets TV; Prieto PA; Vicente D; Hoffman K; Wei SC; Cogdill AP; Zhao L; Hudgens CW; Hutchinson DS; Manzo T; Petaccia de Macedo M; Cotechini T; Kumar T; Chen WS; Reddy SM; Szczepaniak Sloane R; Galloway-Pena J; Jiang H; Chen PL; Shpall EJ; Rezvani K; Alousi AM; Chemaly RF; Shelburne S; Vence LM; Okhuysen PC; Jensen VB; Swennes AG; McAllister F; Marcelo Riquelme Sanchez E; Zhang Y; Le Chatelier E; Zitvogel L; Pons N; Austin-Breneman JL; Haydu LE; Burton EM; Gardner JM; Sirmans E; Hu J; Lazar AJ; Tsujikawa T; Diab A; Tawbi H; Glitza IC; Hwu WJ; Patel SP; Woodman SE; Amaria RN; Davies MA; Gershenwald JE; Hwu P; Lee JE; Zhang J; Coussens LM; Cooper ZA; Futreal PA; Daniel CR; Ajami NJ; Petrosino JF; Tetzlaff MT; Sharma P; Allison JP; Jenq RR; Wargo JA
Science; 2018 Jan; 359(6371):97-103. PubMed ID: 29097493
[TBL] [Abstract][Full Text] [Related]
4. Dysbiosis of skin microbiome and gut microbiome in melanoma progression.
Mekadim C; Skalnikova HK; Cizkova J; Cizkova V; Palanova A; Horak V; Mrazek J
BMC Microbiol; 2022 Feb; 22(1):63. PubMed ID: 35216552
[TBL] [Abstract][Full Text] [Related]
5. The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients.
Matson V; Fessler J; Bao R; Chongsuwat T; Zha Y; Alegre ML; Luke JJ; Gajewski TF
Science; 2018 Jan; 359(6371):104-108. PubMed ID: 29302014
[TBL] [Abstract][Full Text] [Related]
6. The gut microbiome and melanoma: A review.
Makaranka S; Scutt F; Frixou M; Wensley KE; Sharma R; Greenhowe J
Exp Dermatol; 2022 Sep; 31(9):1292-1301. PubMed ID: 35793428
[TBL] [Abstract][Full Text] [Related]
7. The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors.
Joachim L; Göttert S; Sax A; Steiger K; Neuhaus K; Heinrich P; Fan K; Orberg ET; Kleigrewe K; Ruland J; Bassermann F; Herr W; Posch C; Heidegger S; Poeck H
EBioMedicine; 2023 Nov; 97():104834. PubMed ID: 37865045
[TBL] [Abstract][Full Text] [Related]
8. Conversion of unresponsiveness to immune checkpoint inhibition by fecal microbiota transplantation in patients with metastatic melanoma: study protocol for a randomized phase Ib/IIa trial.
Borgers JSW; Burgers FH; Terveer EM; van Leerdam ME; Korse CM; Kessels R; Flohil CC; Blank CU; Schumacher TN; van Dijk M; Henderickx JGE; Keller JJ; Verspaget HW; Kuijper EJ; Haanen JBAG
BMC Cancer; 2022 Dec; 22(1):1366. PubMed ID: 36585700
[TBL] [Abstract][Full Text] [Related]
9. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.
Sivan A; Corrales L; Hubert N; Williams JB; Aquino-Michaels K; Earley ZM; Benyamin FW; Lei YM; Jabri B; Alegre ML; Chang EB; Gajewski TF
Science; 2015 Nov; 350(6264):1084-9. PubMed ID: 26541606
[TBL] [Abstract][Full Text] [Related]
10. The MITRE trial protocol: a study to evaluate the microbiome as a biomarker of efficacy and toxicity in cancer patients receiving immune checkpoint inhibitor therapy.
Thompson NA; Stewart GD; Welsh SJ; Doherty GJ; Robinson MJ; Neville BA; Vervier K; Harris SR; Adams DJ; Dalchau K; Bruce D; Demiris N; Lawley TD; Corrie PG
BMC Cancer; 2022 Jan; 22(1):99. PubMed ID: 35073853
[TBL] [Abstract][Full Text] [Related]
11. A Natural History of Actinic Keratosis and Cutaneous Squamous Cell Carcinoma Microbiomes.
Wood DLA; Lachner N; Tan JM; Tang S; Angel N; Laino A; Linedale R; Lê Cao KA; Morrison M; Frazer IH; Soyer HP; Hugenholtz P
mBio; 2018 Oct; 9(5):. PubMed ID: 30301852
[TBL] [Abstract][Full Text] [Related]
12. [Possible immunotherapies of skin cancers].
Lengyel LZS; Gyulai GYR
Magy Onkol; 2019 Sep; 63(3):239-245. PubMed ID: 31538441
[TBL] [Abstract][Full Text] [Related]
13. Systemic treatments for metastatic cutaneous melanoma.
Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
[TBL] [Abstract][Full Text] [Related]
14. Chronological analysis of the gut microbiome for efficacy of atezolizumab-based immunotherapy in non-small cell lung cancer: Protocol for a multicenter prospective observational study.
Shoji F; Miura N; Tagawa T; Tsukamoto S; Okamoto T; Yamazaki K; Hamatake M; Takeo S
Thorac Cancer; 2022 Oct; 13(19):2829-2833. PubMed ID: 36063818
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous Malignancies of the Head and Neck.
In GK; Thomas JS; Silk AW
Hematol Oncol Clin North Am; 2021 Oct; 35(5):991-1008. PubMed ID: 34281755
[TBL] [Abstract][Full Text] [Related]
16. Gut microbiome and immunotherapy response.
Burki TK
Lancet Oncol; 2017 Dec; 18(12):e717. PubMed ID: 29129446
[No Abstract] [Full Text] [Related]
17. Intratumour microbiome associated with the infiltration of cytotoxic CD8+ T cells and patient survival in cutaneous melanoma.
Zhu G; Su H; Johnson CH; Khan SA; Kluger H; Lu L
Eur J Cancer; 2021 Jul; 151():25-34. PubMed ID: 33962358
[TBL] [Abstract][Full Text] [Related]
18. The cure from within? a review of the microbiome and diet in melanoma.
Kumar P; Brazel D; DeRogatis J; Valerin JBG; Whiteson K; Chow WA; Tinoco R; Moyers JT
Cancer Metastasis Rev; 2022 Jun; 41(2):261-280. PubMed ID: 35474500
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy Not Working? Check Your Microbiota.
West NR; Powrie F
Cancer Cell; 2015 Dec; 28(6):687-689. PubMed ID: 26678336
[TBL] [Abstract][Full Text] [Related]
20. Reduced Staphylococcus Abundance Characterizes the Lesional Microbiome of Actinic Keratosis Patients after Field-Directed Therapies.
Kehrmann J; Koch F; Zumdick S; Höwner A; Best L; Masshöfer L; Scharfenberg S; Zeschnigk M; Becker JC; Schadendorf D; Buer J; Roesch A
Microbiol Spectr; 2023 Jun; 11(3):e0440122. PubMed ID: 37212689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
